Glaukos CEO and leadership

Thomas W. Burns has served as our president, chief executive officer and as a member of our board of directors since March 2002. Mr. Burns has also been a member of the board of directors of DOSE Medical Corporation since October 2009 and its chief executive officer and president since March 2010. Mr. Burns has a proven record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices, ophthalmic pharmaceuticals, drug delivery technologies, surgical products and over-the counter products. Prior to joining our company, Mr. Burns led Eyetech Pharmaceuticals, Inc. (acquired by OSI Pharmaceuticals, Inc.) as its president and chief operating officer, and a director. From 1990 to 1997, Mr. Burns served as senior vice president and general manager of Chiron Vision Corporation (acquired by Bausch & Lomb, Inc.), and then as vice president, global strategy and general manager, refractive surgery of Bausch & Lomb from 1998 to 2000. Mr. Burns has also served as an entrepreneur-in residence at Versant Ventures Management, LLC, an entity affiliated with one of our principal stockholders. Mr. Burns received a B.A. from Yale University. We believe Mr. Burns' extensive understanding of our business, operations and strategy, as well as significant industry experience and corporate management skills and experience qualify him to serve onour board of directors.

Mr. Gilliam is currently the Chief Financial Officer and Senior Vice President, Corporate Development at Glaukos Corporation, and has served in this role since May 2017. Prior to joining Glaukos, Mr. Gilliam held roles of increasing responsibility at JPMorgan over the course of a nearly 20-year financial services career. As a managing director in the healthcare investment banking group his experience spanned mergers and acquisitions, initial and follow-on public equity offerings, bank lending, bond offerings, and other transactions for a variety of companies in the life science tools, diagnostics, biotechnology and medical technology sectors. Mr. Gilliam's prior experience includes positions at The Beacon Group (which was combined with JPMorgan and Chase Manhattan in 2001) and PricewaterhouseCoopers. Mr. Gilliam has a B.S. in accounting from the Kelly School of Business at Indiana University.

Thomas W. Burns has served as our president, chief executive officer and as a member of our board of directors since March 2002. Mr. Burns has also been a member of the board of directors of DOSE Medical Corporation since October 2009 and its chief executive officer and president since March 2010. Mr. Burns has a proven record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices, ophthalmic pharmaceuticals, drug delivery technologies, surgical products and over-the counter products. Prior to joining our company, Mr. Burns led Eyetech Pharmaceuticals, Inc. (acquired by OSI Pharmaceuticals, Inc.) as its president and chief operating officer, and a director. From 1990 to 1997, Mr. Burns served as senior vice president and general manager of Chiron Vision Corporation (acquired by Bausch & Lomb, Inc.), and then as vice president, global strategy and general manager, refractive surgery of Bausch & Lomb from 1998 to 2000. Mr. Burns has also served as an entrepreneur-in residence at Versant Ventures Management, LLC, an entity affiliated with one of our principal stockholders. Mr. Burns received a B.A. from Yale University. We believe Mr. Burns' extensive understanding of our business, operations and strategy, as well as significant industry experience and corporate management skills and experience qualify him to serve onour board of directors.

L. Jay Katz, MD, FACS, is a Professor of Ophthalmology at Jefferson Medical College at Thomas Jefferson University in Philadelphia, Pennsylvania, and the Director of Glaucoma Service at Wills Eye Institute. Dr. Katz received his MD degree from the Yale University School of Medicine. He completed an internship in internal medicine at the University of Virginia, a residency in ophthalmology at Yale University, and a fellowship in glaucoma at Wills Eye Hospital. Dr. Katz has been the recipient of several awards, including the American Academy of Ophthalmology (AAO) Senior Achievement Award in 2002 and the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) Faculty Award in 2003. He was named Distinguished Alumnus of the Yale University Eye Center in 2003 and became an Honored Life Member of the Philadelphia Ophthalmic Club in 2007. Dr. Katz has published more than 120 articles in journals such as Archives of Ophthalmology, the American Journal of Ophthalmology, Ophthalmology and the Journal of Glaucoma. He is an editorial board member for the journals Survey of Ophthalmology, the Journal of Glaucoma, Clinical Therapeutics and Graefes Archive of Clinical and Experimental Ophthalmology. He has authored, coauthored or edited more than 30 books and book chapters.